66.06
-2.26(-3.31%)
Currency In USD
| Previous Close | 68.32 |
| Open | 68.95 |
| Day High | 69.13 |
| Day Low | 65.3 |
| 52-Week High | 76.81 |
| 52-Week Low | 38.51 |
| Volume | 719,850 |
| Average Volume | 688,018 |
| Market Cap | 2.79B |
| PE | -28.85 |
| EPS | -2.29 |
| Moving Average 50 Days | 60.29 |
| Moving Average 200 Days | 49.6 |
| Change | -2.26 |
If you invested $1000 in Tarsus Pharmaceuticals, Inc. (TARS) since IPO date, it would be worth $3,209.91 as of October 26, 2025 at a share price of $66.06. Whereas If you bought $1000 worth of Tarsus Pharmaceuticals, Inc. (TARS) shares 3 years ago, it would be worth $3,814.09 as of October 26, 2025 at a share price of $66.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 9:00 PM GMT
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire Inc.
Apr 24, 2025 9:00 PM GMT
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial res
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
GlobeNewswire Inc.
Apr 22, 2025 12:31 PM GMT
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XD